A Patient Charter for Chronic Obstructive Pulmonary Disease (COPD)

John R. Hurst · Tonya Winders · Heinrich Worth · Mohit Bhutani · Kevin Gruffydd-Jones · Daiana Stolz · Mark T. Dransfield

Foreword

384 million people worldwide are affected by COPD.¹

The third leading cause of death among heart disease and stroke.¹ As global patient advocates, we believe it is essential to raise the level of awareness and understanding among patients, caregivers, healthcare professionals, policymakers and the public about the impact of COPD and opportunities to reform patient care. We believe patients should be empowered to live freely with COPD, without symptoms and exacerbations, reducing their interaction with hospitals and extending their life for as long as possible.

Tonya A. Winders
President & CEO
Allergy & Asthma Network

President
Global Allergy & Airways Patient Platform
Introduction

COPD is estimated to affect 384 million people worldwide.¹

Chronic Obstructive Pulmonary Disease (COPD) is a group of progressive lung conditions most commonly characterised by persistent respiratory symptoms (chronic cough, shortness of breath and sputum production) and lung function impairment due to airflow limitation and/or hyperinflation. The severity of symptoms, lung function impairment and experience of exacerbations (also known as flare ups) vary between patients.²

The global burden of COPD is growing. In 2015, 3.2 million people died from COPD worldwide, an increase of 11.6 per cent compared to 1990.³ COPD also places significant burden on the global economy, with an estimated cost of greater than $100 billion per year globally.²,⁴,⁵

Global strategy documents and guidelines exist, including those from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the American Thoracic Society (ATS), which define best practices in COPD care based on the latest evidence. National guidelines also exist which vary in measures of disease severity, consideration of patient phenotype and treatment criteria,⁶ demonstrating inconsistencies in how COPD patients are managed at a global and national level. In addition, almost 90 per cent of cases of COPD worldwide are not diagnosed⁷ and adherence to therapy guidelines can be poor.⁸,⁹

Representatives of three national patient organisations along with seven clinicians discussed the value of establishing a Patient Charter as a potential starting point for discussions on how to reform care for patients with COPD. This Charter was subsequently initiated and funded by AstraZeneca and aims to set a standard for what people with COPD should expect from their ongoing care. These expectations are in line with the current best practice understanding from existing COPD services, to offer consensus on global standards of COPD care and drive timely, evidence-based treatment to maintain health status, minimise symptoms and prevent exacerbations. The purpose of this Charter is to mobilise governments, healthcare providers, policymakers, lung health industry partners and patients/caregivers to address the unmet need and burden in COPD, ultimately working together to deliver meaningful improvements in care, both now and in the future.

Six principles of quality care for people with COPD

This Charter outlines six principles of quality care that patients should expect to receive, wherever they live. The principle concepts were developed by a working group of 20 clinicians and patient advocacy group representatives and refined by the committee of experts who authored the COPD Patient Charter.
• Symptoms in the early stages of COPD can be mild, meaning they are not always well recognised by patients, who often assume their symptoms are a result of ageing, or smoking\(^{19}\)
• As such, COPD is frequently diagnosed late when the disease has already progressed. This is associated with higher rates of exacerbations, increased multimorbidities and costs\(^{11}\)
• Undiagnosed COPD also places significant burden on patients and the healthcare system. However, these patients are not recognised by healthcare professionals as having the disease and therefore not being properly managed and treated. Almost 90 per cent of cases of COPD may be undiagnosed worldwide\(^7\) and they use healthcare services for their symptoms in the same way as diagnosed patients\(^{12}\)
• Currently, there are no therapies that affect the rate of change once lung function has started to decline.\(^{13}\) Controlling symptoms, preventing exacerbations and early death is therefore essential for people living with COPD
• Accurate diagnosis of COPD can only be made using spirometry, a physiological test to assess the reversibility of airflow limitation, which should be performed and interpreted by trained individuals.\(^2\) However, this assessment alone is not recommended to inform treatment decisions\(^2\) meaning that other diagnostic tools are also required
• Patients and healthcare professionals should have the tools to support them to recognise the initial symptoms of COPD and access to the right resources; including electronic medical records and diagnostic tests; to make an informed and accurate diagnosis
COPD is a heterogeneous disease, which can be categorised based on symptom severity and history of exacerbations at initial diagnosis. However, as a progressive disease, symptoms may change or worsen over time and can lead to exacerbations. COPD is also associated with a number of multimorbidities, which further contribute to disease severity, reduced quality of life, and poor clinical outcomes. These factors should drive a change in how the condition is managed (both the pharmacological and non-pharmacological management).

With increasing demand for COPD services, it is becoming more important for patients to become active participants in their own care and respond to their symptoms with urgency to prevent further disease progression.

Self-management interventions in patients with COPD are associated with improved health-related quality of life, a reduction in hospital admissions, and improvement in symptoms.

Patients should receive personalised education and training about their COPD and how it interacts with their other morbidities to enable them to actively participate in their own care, implementing long term changes and reporting changes in symptoms to their healthcare professional to prevent further disease progression.
• Goals for the treatment of COPD are based on reducing symptoms and the risk of future exacerbations, preventing lung function decline and premature death.\textsuperscript{2} Many therapies have been shown to be beneficial across these goals, including suggestions of reduced mortality\textsuperscript{17,18,19}
• Many gaps exist in non-pharmacological (for example, pulmonary rehabilitation, including exercise training and education, and smoking cessation) and pharmacological management of COPD. Over two thirds of people are not prescribed maintenance therapy\textsuperscript{20} and, of those receiving treatment, up to three quarters of people who experience two or more exacerbations continue to be undertreated according to GOLD recommendations\textsuperscript{21}
• COPD is a heterogenous disease meaning that symptom severity, history of exacerbations, multimorbidities, impact on quality of life and biological markers will vary between and within patients and management of COPD should be personalised to the individual patient
• COPD patients should request an evidence-based and personalised management plan at both initial diagnosis and follow-up to enable a more proactive, timely prevention of disease progression rather than reacting to a worsening of health status
Exacerbations have a detrimental impact on patients and society. Hospitalisations resulting from severe exacerbations account for approximately two thirds of all healthcare costs associated with COPD. Frequent moderate (community treated) exacerbations or one severe (hospital) exacerbation increases a patient risk of death. Over 70 per cent of patients with COPD experience exacerbations within three years of diagnosis and a history of exacerbations is the best predictor of future risk. Exacerbations are associated with an increased risk of cardiovascular complications, such as myocardial infarctions (MI) and strokes. The risk of MI doubles within 5 days of the start of an exacerbation, and then returns to baseline over time, and the risk of stroke increases by 40 per cent within ten days. Exacerbations also appear to have a significant impact on mental and emotional well-being, and this may be underestimated by clinicians. Despite this, COPD exacerbations are not responded to with urgency. The current global treatment paradigm is one of failure-driven escalation, whereby escalation in treatment is considered following a worsening of symptoms, such as exacerbations. However, only 25 per cent patients received maintenance therapy, treatments offered to prevent or reduce symptoms, after an exacerbation and over half of exacerbations go unreported. National policymakers and healthcare professionals should appreciate the significant burden associated with COPD and ensure exacerbations trigger a review of management and address the current global treatment paradigm of failure driven escalation, shifting to evidence-based treatment to maintain health status, minimise symptoms and prevent future exacerbations.
Specialist care refers to care provided by a healthcare professional who has the expert skills and understanding of COPD to provide appropriate care.

Staffing levels and the availability of specialist respiratory review is linked to reduced risk of death and quality of service in COPD.32,33 People who received specialist review within 24 hours of admission to hospital for a severe exacerbation were 14 per cent less likely to die as an inpatient compared to those who did not receive specialist review.33

Similarly, barriers exist in access to outpatient specialist COPD services and pulmonary rehabilitation. This is mainly attributed to limited resources, particularly within rural areas.34

However, with digital technologies, including remote consultations, COPD should become a benchmark of how such technologies can improve current services and enable the provision of tailored, specialist care, regardless of where a person lives.
Worldwide, the most common risk factor for COPD is tobacco smoking and, as a result, there is a stigma associated with the condition. As a result of this stigma, many patients experience self-blame, guilt and shame. People with COPD also describe feeling stigmatised by healthcare professionals in some cases, which can lead to reluctance to access treatment. However, it is becoming clear COPD is not solely linked to tobacco smoking. There are a number of other risk factors linked with the condition, including indoor (household) and outdoor air pollution, genetic predispositions, abnormal lung developments and accelerated ageing.

Healthcare professionals, patients and the general public should be educated about the numerous risk factors associated with COPD in order to reduce the associated stigma of the condition, ensuring that people are not discouraged from seeking help.
References

1 WHO. The top 10 causes of death. Available at: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. [Accessed: October 2020]

2 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for diagnosis, management and prevention of COPD. 2020. Available at: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf [Accessed: October 2020]

3 GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systemic analysis for the Global burden of Disease Study 2015. The Lancet Respiratory Medicine. 2017; 5(9):691-706.

4 Chen, X. et al. Costs of chronic obstructive pulmonary disease in urban areas of China: a cross-sectional study in four cities. International journal of chronic obstructive pulmonary disease. 2016; 2625.

5 Nishimura, S. and Zaher, C. Cost impact of COPD in Japan: opportunities and challenges?. Respiratory. 2004; 9; 466-473.

6 Miravitlles, M., Vogelmeier, C., Roche, N., et al. A review of national guidelines for management of COPD in Europe. European Respiratory Journal. 2016; 47(2), 625-637.

7 Gershon, AS., Hwee, J. et al. Factors associated with undiagnosed and overdiagnosed COPD. Eur Respir J. 2016; 48: 561–4.

8 Price, D., West, D., Brusselle, G., et al. Management of COPD in the UK Primary-Care Setting: An Analysis of Real-Life Prescribing Patterns. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9; 889–904.

9 Albital, HA., Iyer, VN. Adherence to Global Initiative for Chronic Obstructive Lung Disease Guidelines in the Real World: Current Understanding, Barriers, and Solutions. Curr. Opin. Pulm. Med. 2019.

10 Leidy, NK. et al. Identifying cases of undiagnosed, clinically significant COPD in primary care: qualitative insight from patients in the target population. NPJ primary care respiratory medicine. 2015; 24.

11 Larsson, K., Janson, C., Stallberg, B. et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. Int J Chron Obstruct Pulmon Dis. 2019; 14: 995 – 1008.

12 Labonté, LE. et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD study. American journal of respiratory and critical care medicine. 2016; 194(3):285-98.

13 Medscape. Chronic Obstructive Pulmonary Disease (COPD) Treatment & Management. 2019. Available at: https://emedicine.medscape.com/article/297664-treatment [Accessed: October 2020]

14 Negewo, NA., McDonald, VM., Gibson, PG. Comorbidity in chronic obstructive pulmonary disease. Respiratory investigation. 2015; 53(6):249-58.

15 Westerik, JA., et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respiratory research. 2017; 18(1);31.

16 Zwerink, M. et al. Self management for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2014(3).

17 Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948-55.

18 Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in COPD patients. Am J Respir Crit Care Med. 2020.

19 Scmir M, Fabbri LM, Singh D, et al. Reduction in fatal events with ICS-containing medications: results of safety pooled analysis from the TRILOGY, TRINITY and TRIBUTE studies [abstract]. Am J Respir Crit Care Med. 2018;197:A7725.

20 Make B. et al. Undertreatment of COPD: A Retrospective Analysis of US Managed Care and Medicare Patients. Int. J. Chron. Obstruct. Pulmon. Dis. 2012; 7; 1–9.

21 Halpin DMG, et al. Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019. EClinicalMedicine 2019; 14, 32–41.

22 Halpin DM, Miravitlles, M., Metzdorf, N., Celli, B. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2891–2908.

23 Rothnie KJ., Müllerová, H., Smeeth, L., Quint, JK. Natural history of chronic obstructive pulmonary disease exacerbations in a general practice–based population with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2018; 198:464–471.
24 Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017; 5(8): 619 – 626.
25 Hoogendoorn M, Feenstra TL, Boland M et al. Prediction models for exacerbations in different COPD patient population: comparing results from five large data sources. Int J Chron Obstruct Pulmon Dis. 2017; 12:3183 – 3194.
26 Tashkin DP, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 369:1543 – 54.
27 Müllerová H. et al. Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study. BMJ open. 2014; e006171.
28 Donaldson GC., Hurst, JR., Smith, CJ. et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010; 137(5):1091 – 1097.
29 Kessler R. et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006; 130(1), 133-142.
30 Dalal A. et al. Observational study of the outcomes and costs of initiating maintenance therapies in patients with moderate exacerbations of COPD. Respiratory research. 2012; 41.
31 Xu W. et al. Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. European Respiratory Journal. 2010; 35(5): 1022-30.
32 Hartl S., Lopez-Campos JL., Pozo-Rodriguez F. et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016; 47(1): 113 – 21.
33 Royal College of Physicians. COPD clinical Audit 2017/18. National Asthma and COPD Audit Programme (NACAP). Available at: https://www.rcplondon.ac.uk/projects/outputs/national-asthma-and-copd-audit-programme-nacap-copd-clinical-audit-201718 [Accessed: October 2020]
34 EFA. Minimum Standards of Care for COPD Patients in Europe. Available at: https://www.efanet.org/images/2014/10/EFA-Book-Minimum-Standards-of-Care-for-COPD-Patients-in-Europe_ENGLISH.pdf [Accessed: October 2020]
35 Russell S. et al. Qualitative systematic review of barriers and facilitators to self-management of chronic obstructive pulmonary disease: views of patients and healthcare professionals. NPJ primary care respiratory medicine. 2018; 28(1):1-3.
36 Lippiett KA., Richardson, A., Myall, M. et al. Patients and informal caregivers’ experiences of burden of treatment in lung cancer and chronic obstructive pulmonary disease (COPD): a systematic review and synthesis of qualitative research. BMJ Open. 2019; 9:e020515.